Sleep restriction increases free fatty acids in healthy men
Sleep loss is associated with insulin resistance and an increased risk for type 2 diabetes, yet underlying mechanisms are not understood. Elevation of circulating non-esterified (i.e. free) fatty acid (NEFA) concentrations can lead to insulin resistance and plays a central role in the development of metabolic diseases. Circulating NEFA in healthy individuals shows a marked diurnal variation with maximum levels occurring at night, yet the impact of sleep loss on NEFA levels across the 24 h cycle remains unknown. We hypothesised that sleep restriction would alter hormones that are known to stimulate lipolysis and lead to an increase in NEFA levels.
We studied 19 healthy young men under controlled laboratory conditions with four consecutive nights of 8.5 h in bed (normal sleep) and 4.5 h in bed (sleep restriction) in randomised order. The 24 h blood profiles of NEFA, growth hormone (GH), noradrenaline (norepinephrine), cortisol, glucose and insulin were simultaneously assessed. Insulin sensitivity was estimated by a frequently sampled intravenous glucose tolerance test.
Sleep restriction relative to normal sleep resulted in increased NEFA levels during the nocturnal and early-morning hours. The elevation in NEFA was related to prolonged nocturnal GH secretion and higher early-morning noradrenaline levels. Insulin sensitivity was decreased after sleep restriction and the reduction in insulin sensitivity was correlated with the increase in nocturnal NEFA levels.
Sleep restriction in healthy men results in increased nocturnal and early-morning NEFA levels, which may partly contribute to insulin resistance and the elevated diabetes risk associated with sleep loss.
KeywordsCatecholamines Cortisol Free fatty acids Glucose Growth hormone Insulin sensitivity Lipolysis Metabolism NEFA Sleep loss Sleep restriction Type 2 diabetes
Rapid eye movement
Non-esterified fatty acid
Intravenous glucose tolerance test
Substantial evidence from population studies suggests that individuals who regularly curtail their sleep are at an increased risk for developing type 2 diabetes . Several well-controlled laboratory studies have consistently shown marked reductions in insulin sensitivity in young adults following sleep loss [2, 3, 4, 5, 6, 7]. However, the mechanisms by which insufficient sleep increases type 2 diabetes risk are not known. Alterations in non-esterified (i.e. free) fatty acid (NEFA) levels play a central role in the pathogenesis of insulin resistance and the development of metabolic diseases [8, 9]. Acute elevation in circulating NEFA levels in healthy individuals has been linked to insulin resistance in multiple investigations [10, 11, 12, 13]. A marked diurnal variation in circulating NEFA concentrations has been observed in healthy individuals with peak levels occurring in the middle of the night and declining levels towards morning . To date, the impact of sleep loss on NEFA concentrations across the 24 h cycle remains unknown.
Growth hormone (GH), noradrenaline (norepinephrine) and cortisol are major signals that link the central nervous system to peripheral tissues. In addition, these hormones are known to increase the rate of lipolysis, resulting in elevated circulating NEFA concentrations. Experimental sleep restriction in healthy young adults has been associated with alterations in nocturnal GH secretion , increased night-time noradrenaline concentrations  and elevated evening cortisol levels [4, 16, 17]. We therefore hypothesised that sleep loss would alter these lipolytic hormones, leading to an increase in NEFA concentrations. To test this hypothesis, we simultaneously assessed 24 h blood profiles of NEFA, GH, noradrenaline and cortisol in healthy volunteers who were tested in the laboratory under conditions of normal sleep and sleep restriction. We also assessed 24 h glucose and insulin profiles and estimated insulin sensitivity by an intravenous glucose tolerance test during normal sleep and sleep restriction.
Nineteen healthy young lean men between 18 and 30 years of age were recruited from the community through local advertisements. Exclusion criteria were a history of any chronic medical condition, acute illness, shift work, travel across time zones during the past 4 weeks, depressed mood (as assessed by a score on the Center for Epidemiologic Studies of Depression Scale >16), use of any prescription or over-the-counter medications or supplements known to affect sleep or glucose metabolism, current smoking, substantial consumption of alcohol (>2 drinks per day) or caffeine (>300 mg per day) or abnormal findings on physical examination or routine laboratory testing. All participants had an overnight laboratory polysomnography to exclude sleep disorders, as well as a standard 75 g oral glucose tolerance test and fasting blood sample collection for routine laboratory tests, including complete blood counts, a comprehensive metabolic panel, thyroid function tests, a lipid panel and HbA1c measurement. A 12-lead electrocardiogram was also obtained to screen for sleep abnormalities. Healthy participants who had normal glucose tolerance and no current or previous sleep disorders were included. All participants had regular self-reported nocturnal time in bed of 7.5–8.5 h. The Institutional Review Board of the University of Chicago approved the protocol and all participants gave written informed consent.
Participants were studied at the University of Chicago Clinical Resource Center under two experimental conditions in randomised order spaced at least 4 weeks apart: (1) four consecutive nights of 8.5 h in bed (normal sleep) and (2) four consecutive nights of 4.5 h in bed (sleep restriction). Sleep was recorded by polysomnography (Nihon Kohden, Irvine, CA, USA) during each night in each sleep condition. The recordings were visually scored in 30 s epochs as rapid eye movement (REM) sleep, non-REM sleep and wake according to standard criteria . Participants remained in the laboratory during the entire protocol and participated in sedentary activities (e.g. reading, watching TV, computer work, board or card games, etc.). A research staff member was continuously present to monitor wakefulness. During the week preceding each inpatient period, participants maintained standardised bedtimes at home in accordance with their usual habits. Naps were not allowed. Compliance with this schedule was verified by sleep diaries and continuous wrist activity monitoring (Actiwatch; Philips-Respironics, Bend, OR, USA).
All hormonal values were interpolated at 15 min intervals to facilitate chronobiological analyses. The NEFA profiles were smoothed using a two-point moving average to facilitate the identification of the onset and peak nocturnal NEFA levels. To better assess the relationships between the GH secretion and NEFA rise, the nocturnal NEFA onset was defined as the minimum NEFA value occurring after the onset of the first GH pulse. The nocturnal NEFA peak was defined as the maximum NEFA value that occurred after the sleep-onset GH pulse. The duration of nocturnal NEFA rise was calculated from NEFA onset to peak. Significant GH secretory pulses were identified as previously described . The duration of nocturnal GH secretion was defined as the total duration of significant GH secretory pulses (concentration above 0.3 ng/ml) from the onset of the first GH pulse after blood sampling began until the end of the sleep-onset GH pulse.
Blood samples were centrifuged immediately at 4°C and plasma was frozen and stored at −80°C until assay. For each 24 h profile, all samples obtained from the same individual were measured in the same assay. Plasma NEFA levels were measured using a colorimetric assay (Wako Chemicals, Richmond, VA, USA). Plasma glucose was assayed by the glucose oxidase method with a coefficient of variation < 2%. Serum insulin and plasma cortisol and GH were measured by chemiluminescence assays using the Immulite Immunochemistry System (Diagnostic Products Corporation, Los Angeles, CA, USA). Plasma noradrenaline was measured using an HPLC system (Coulochem MD5001; ESA, Chelmsford, MA, USA) with a lower limit of sensitivity of 10 pg/ml and an intra-assay coefficient of variation of 6–7.8%.
The effects of sleep restriction on metabolic variables were assessed using repeated measures design by mixed-model ANOVA with participants as random factor and sleep conditions (normal sleep, sleep restriction) as fixed factors. The NEFA time points between normal sleep and sleep restriction conditions were analysed by mixed-model ANOVA with participants as random factor and sleep condition and sampling time as fixed factors after controlling for multiple comparisons with a Benjamini and Hochberg procedure. Changes in hormonal and metabolic variables following sleep restriction were expressed as percentage of the values obtained during normal sleep. Relationships between changes in NEFA levels and changes in other metabolic variables were examined using the Pearson coefficient. Data are reported as mean and SEM. All statistical analyses were performed using JMP software (version 9.0.3; SAS Institute, Cary, NC, USA). A p value < 0.05 was considered significant for all analyses.
Effects of sleep restriction on sleep stages
20.6 ± 1.4
6.1 ± 0.5
4.5 ± 0.3
2.4 ± 0.2
248.3 ± 4.9
118.9 ± 4.8
53.1 ± 1.0
45.8 ± 1.8
Slow wave sleep, min
74.2 ± 6.4
77.7 ± 5.5
Slow wave sleep, %
15.9 ± 1.3
30.0 ± 2.1
124.8 ± 4.5
57.0 ± 2.6
26.6 ± 0.86
21.9 ± 1.0
26.1 ± 2.3
7.0 ± 1.3
5.7 ± 0.6
2.8 ± 0.6
247.1 ± 5.0
115.6 ± 6.9
53.8 ± 1.4
44.8 ± 2.5
Slow wave sleep, min
68.9 ± 6.8
72.1 ± 6.4
Slow wave sleep, %
14.9 ± 1.4
28.1 ± 2.5
118.5 ± 6.8
62.7 ± 3.7
25.6 ± 1.3
24.3 ± 1.4
Effects of sleep restriction on 24 h profiles of NEFA, GH, noradrenaline and cortisol
Nocturnal onset, mmol/l
0.15 ± 0.01
0.15 ± 0.01
Nocturnal peak, mmol/l
0.66 ± 0.03
0.69 ± 0.04
Duration of nocturnal increase, min
210 ± 15
262 ± 15
Mean nocturnal (04:00–05:45 hours), mmol/l
0.44 ± 0.02
0.51 ± 0.03
Mean early morning (07:15–09:00 hours), mmol/l
0.24 ± 0.02
0.31 ± 0.02
Mean daytime (09:00–21:30 hours), mmol/l
0.10 ± 0.01
0.09 ± 0.01
Duration of nocturnal secretion, min
307 ± 18
359 ± 20
Nocturnal amount secreted, μg
726 ± 59
614 ± 57
Daytime amount secreted, μg
127 ± 21
103 ± 17
Mean early night (23:00–01:00 hours), pmol/l
633 ± 52
833 ± 94
Mean early morning (05:30–07:30 hours), pmol/l
676 ± 50
868 ± 90
Mean daytime (09:00–21:30 hours), pmol/l
1,064 ± 74
1,085 ± 98
Mean early night (23:00–01:00 hours), nmol/l
51 ± 5
75 ± 9
Mean evening (19:00–21:30 hours), nmol/l
119 ± 12
146 ± 12
During normal sleep, a single nocturnal GH pulse was observed in all but four of the 19 participants (Fig. 2b). In contrast, during sleep restriction 14 of the 19 participants showed a biphasic nocturnal GH release, resulting in GH secretion being prolonged by approximately 50 min. The total amount of nocturnal GH secreted did not differ between sleep conditions (Table 2). The increase in the duration of nocturnal GH secretion was correlated with the prolonged duration of NEFA rise (r = 0.81, p < 0.0001), while no relationship was found with the amount of nocturnal GH (r = 0.30, p = 0.207). Noradrenaline levels were increased by approximately 30% during the early-night and early-morning hours, when participants had to remain awake during sleep restriction (Fig. 2c, Table 2). This early-night increase in noradrenaline did not appear to influence the NEFA peak or the slope of NEFA rise. However, the early-morning increase in noradrenaline was positively correlated with the early-morning increase in NEFA levels (r = 0.55, p = 0.015). The normal post-awakening cortisol peak occurred approximately 2 h earlier when sleep was restricted (Fig. 2d) and cortisol levels were 23% higher in the evening hours as well as during the early night with extended wakefulness (Table 2). The alterations in cortisol secretory patterns did not correlate with any changes in NEFA (p > 0.05 for all variables).
We have demonstrated that experimental sleep restriction in healthy young lean men results in an increase in nocturnal and early-morning NEFA levels accompanied by insulin resistance. We also found that alterations in two lipolytic hormones, namely GH and noradrenaline, may be involved in the observed increase in NEFA levels during sleep restriction. These findings provide novel insights into our understanding of the pathways that may link sleep restriction to insulin resistance and increased diabetes risk.
To our knowledge, this is the first study to examine the impact of sleep loss on 24 h NEFA profiles. We observed the maximum NEFA levels occurring at night, as reported in earlier studies [20, 21, 22, 23]. When sleep was restricted, the NEFA levels remained elevated during the nocturnal and early-morning hours in the prolonged fasted state. However, daytime NEFA levels were similar between sleep conditions, suggesting that sleep restriction may differentially affect NEFA levels during fasting vs fed states. Thus far, two studies have explored the effects of sleep deprivation on NEFA concentrations, but measurements were taken only in the morning over a limited number of time points [24, 25]. In the first study, NEFA concentrations were measured following one night of total sleep deprivation and recovery sleep in overweight individuals. Morning fasting and postprandial NEFA concentrations were found to be lower after recovery sleep as compared with baseline . In the second study, 2 weeks of sleep restriction during diet-induced weight loss resulted in increased morning fasting NEFA levels in overweight adults .
To examine the potential signals that may be involved in elevations in NEFA during sleep restriction, we simultaneously assessed 24 h profiles of GH, noradrenaline and cortisol (i.e. hormones that are known to stimulate lipolysis and link the central nervous system to peripheral metabolism). We found that the nocturnal GH secretory pattern became biphasic during sleep restriction, relative to normal sleep, resulting in extended GH secretion, as previously reported . The increase in the duration of nocturnal GH secretion was strongly related to the prolonged nocturnal increase in NEFA, suggesting that an altered GH secretory pattern may be partially responsible for the observed increase in nocturnal NEFA levels during sleep restriction. However, it is also possible that the prolonged exposure of peripheral tissues to higher GH levels may directly affect glucose and lipid regulation at the tissues themselves.
We also found that noradrenaline levels were elevated during the early-night and early-morning hours when participants had to remain awake during the sleep restriction condition, consistent with the known inhibitory effect of sleep on noradrenaline . The increase in early-morning noradrenaline was positively correlated with the increase in early-morning NEFA levels, suggesting that higher noradrenaline levels likely contributed to the interruption of decline in morning NEFA concentrations during sleep restriction. Our finding of elevated noradrenaline supports the hypothesis that augmented sympathetic drive may be a potential mediator of the metabolic consequences of sleep restriction and is in agreement with some  but not all [24, 27] studies reporting increased sympathetic activity with sleep loss.
Consistent with earlier reports [4, 28], we found an increase in evening cortisol levels during sleep restriction. Additionally, we observed an earlier cortisol peak during sleep restriction relative to normal sleep, likely due to the stimulating effects of morning awakening. During the early night, cortisol levels were higher when sleep was restricted, possibly due to the lack of inhibitory effects of the early sleep period. However, we did not find any correlations between changes in cortisol secretion and NEFA levels. Although this may suggest that cortisol is not a key mediator of NEFA release during sleep restriction, we cannot exclude the interactions and combined effects of various hormones, including cortisol, that are affected by sleep loss.
As shown previously in multiple studies [3, 4, 5, 6, 29], we observed reduced insulin sensitivity in our participants in the morning hours during sleep restriction as compared with normal sleep. The reduction in morning insulin sensitivity was correlated with the increase in nocturnal NEFA levels. Although this correlation does not demonstrate a direct causal link, acute elevation in circulating NEFA concentrations has been shown to induce insulin resistance in healthy participants in multiple previous studies [10, 11, 12, 13]. In addition, the degree of insulin resistance in patients with type 2 diabetes correlates with the elevation in nocturnal NEFA levels . Although the increase in NEFA levels during sleep restriction was modest (an increase of approximately 15–30% during nocturnal and early-morning hours) in our healthy participants, these findings are consistent with the notion that even a very small sustained increase in NEFA concentrations can alter insulin sensitivity . Our findings are also in agreement with the observation of elevated nocturnal NEFA levels in a dog model of diet-induced insulin resistance . Although we did not find significant correlations between decreased insulin sensitivity and changes in cortisol, noradrenaline or GH, alterations in these factors are known to affect insulin sensitivity and thus may be additional mediators of the insulin-resistant state that we observed in our participants.
Future mechanistic studies (e.g. use of pharmacological agents to suppress NEFA) will be necessary to demonstrate a direct causal role for NEFA in insulin resistance induced by sleep loss. Our current finding of elevated NEFA also suggests that adipocytes are resistant to the antilipolytic effects of insulin, and thus is consistent with our previous report of impaired intracellular insulin signalling in adipose tissue following sleep restriction . It is important to note that our study does not provide information on the long-term effects of sleep restriction or the effects of recovery sleep following short-term sleep restriction on NEFA levels or insulin sensitivity.
We cannot exclude the possibility that altered circadian timing may play a role in our findings. Sleep and circadian rhythms are highly integrated such that sleep loss can occur with circadian misalignment and studies of sleep restriction have shown evidence for altered circadian timing [33, 34]. Disruption of circadian rhythms has also been associated with adverse effects on metabolism [29, 35]. Additionally, recent findings suggest the importance of clock genes in regulating lipolytic activity in adipose tissue . Future studies are required to determine the independent effects of dysregulated circadian timing on NEFA metabolism.
In summary, we have demonstrated that sleep restriction in healthy young men results in elevations in nocturnal and early-morning NEFA levels accompanied by marked alterations in hormones involved in lipolysis and reduced insulin sensitivity. These findings provide evidence for potential mechanisms by which sleep restriction may be associated with insulin resistance and increased type 2 diabetes risk. From a clinical perspective, our findings support the importance of sleep in the regulation of metabolism and provide further evidence that insufficient sleep, a highly prevalent condition in our modern society, may adversely affect fatty acid metabolism. Future studies are required to discover whether achieving adequate sleep can improve metabolic outcomes and thus be a novel strategy to counteract the current epidemics of diabetes and obesity.
The authors wish to thank E. Van Cauter, Department of Medicine, University of Chicago, for her expertise and intellectual contributions to this manuscript. We thank T. Marcinkowski, Department of Medicine, University of Chicago, for performing the noradrenaline assays, P. Rue, Department of Medicine, University of Chicago, for performing the insulin and GH assays, the nursing and dietary staff of the University of Chicago General Clinical Resource Center for their expert assistance and the volunteers for participating in this study.
This work was supported by NIH grants R01-HL-075079, P01-AG11412, CTSA-UL1 TR000430, P50-HD057796, P60-DK20595, Department of Defense award W81XWH-07-2-0071 and Society in Science—The Branco Weiss Fellowship (to JLB).
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
JLB contributed to study design, data acquisition and analysis and wrote the manuscript. FC, VA, AD, FD and HRW contributed to data acquisition and analysis, reviewed and edited the manuscript for intellectual content. ET obtained funding, designed the study, collected and analysed data and wrote the manuscript. All authors gave final approval of the version to be published. ET is the guarantor of this work.
- 5.Nedeltcheva AV, Kessler L, Imperial J, Penev PD (2009) Exposure to recurrent sleep restriction in the setting of high caloric intake and physical inactivity results in increased insulin resistance and reduced glucose tolerance. J Clin Endocrinol Metab 94:3242–3250CrossRefPubMedCentralPubMedGoogle Scholar
- 8.DeFronzo RA (2004) Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pract 58(Suppl 143):9–21Google Scholar
- 13.Yoshino J, Almeda-Valdes P, Patterson BW et al (2014) Diurnal variation in insulin sensitivity of glucose metabolism is associated with diurnal variations in whole-body and cellular fatty acid metabolism in metabolically normal women. J Clin Endocrinol Metab 99:E1666–E1670CrossRefPubMedGoogle Scholar
- 15.Spiegel K, Leproult R, Colecchia E et al (2000) Adaptation of the 24-hour growth hormone profile to a state of sleep debt. Am J Physiol 279:R874–R883Google Scholar
- 18.Iber C, Ancoli-Israel S, Chesson A, Quan S (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specification. American Academy of Sleep Medicine, WestchesterGoogle Scholar
- 28.Chapotot F, Buguet A, Gronfier C, Brandenberger G (2001) Hypothalamo-pituitary-adrenal axis activity is related to the level of central arousal: effect of sleep deprivation on the association of high-frequency waking electroencephalogram with cortisol release. Neuroendocrinology 73:312–321CrossRefPubMedGoogle Scholar